Health TrialsbyHealthPanel

Primary and Secondary Drug Resistance Mutations (DRMs) in HIV As a Risk Factor of Failure of ART, Including Two Drugs Based Regimens.

ConditionsHIV-1-infectionDRMDRM Gene MutationART
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorMedical University of Warsaw

About this trial

The presence of drug resistance mutations (DRMs) in HIV plays an important role in ART effectiveness. Despite very good results of ART, there is constant concern about the emergence of HIV strains with DRMs, what may lead to virological suppression failure. The concerns grow especially among patients treated with two drugs based regimens, including long acting therapies in injections (LAI ART) or regimens used in preexposure prophylaxis (PreP).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

HIV- 1 diagnosed patient recruited in three clinical centers in Poland (two in Warsaw, one in Ostróda)

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

  • no intervention

    Other intervention

    no intervention

Treatment groups

200 Participants
are divided into 2 treatment groups
Group A: primary DRMs1 intervention
Group B: secondary DRMs1 intervention

Trial outcomes

Primary outcomes

1

frequency of DRMs

frequency of DRMs in all included patients

Time frame
2 years

Secondary outcomes

1

frequency of primary and secondary DRMs

frequency of primary and secondary DRMs, including resistance to InSTI

Time frame
2 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Medical University of Warsaw

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: